The median age at diagnosis of chronic myeloid leukemia (CML) is between 60 and 65 years in most epidemiologic registries. Rather than age per se, a comprehensive evaluation of comorbidities may describe more properly the general clinical status of a patient. Tyrosine-kinase inhibitors (TKIs) have a different tolerability profile, and some adverse events (AEs) are peculiar of each drug, in particular, in presence of predisposing factors (comorbidities, concomitant medications). This article will review the impact of comorbidities in the safety and outcome of CML patients treated with TKIs. We will explore how the comorbidity status may be considered, together with CML-related factors, in the selection of the TKI in order to optimize treatment.

Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors / Gugliotta G;Castagnetti F;Fogli M;Cavo M;Baccarani M;Rosti G. - In: EXPERT REVIEW OF HEMATOLOGY. - ISSN 1747-4086. - STAMPA. - 6:(2013), pp. 563-574. [10.1586/17474086.2013.837279]

Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.

GUGLIOTTA, GABRIELE;CASTAGNETTI, FAUSTO;FOGLI, MIRIAM;CAVO, MICHELE;BACCARANI, MICHELE;ROSTI, GIANANTONIO
2013

Abstract

The median age at diagnosis of chronic myeloid leukemia (CML) is between 60 and 65 years in most epidemiologic registries. Rather than age per se, a comprehensive evaluation of comorbidities may describe more properly the general clinical status of a patient. Tyrosine-kinase inhibitors (TKIs) have a different tolerability profile, and some adverse events (AEs) are peculiar of each drug, in particular, in presence of predisposing factors (comorbidities, concomitant medications). This article will review the impact of comorbidities in the safety and outcome of CML patients treated with TKIs. We will explore how the comorbidity status may be considered, together with CML-related factors, in the selection of the TKI in order to optimize treatment.
2013
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors / Gugliotta G;Castagnetti F;Fogli M;Cavo M;Baccarani M;Rosti G. - In: EXPERT REVIEW OF HEMATOLOGY. - ISSN 1747-4086. - STAMPA. - 6:(2013), pp. 563-574. [10.1586/17474086.2013.837279]
Gugliotta G;Castagnetti F;Fogli M;Cavo M;Baccarani M;Rosti G
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/396010
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 17
social impact